Alto Neuroscience Inc（ANRO）の株式分析ANROAlto Neuroscience Inc

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $21.97 and the RSI of 36.373, which indicates the stock is in oversold territory, it may be wise to hold rather than buy at this moment. The stock has seen a significant drop of 17.06% over the last 20 days, indicating volatility. Additionally, insider selling has increased by 159.20% over the last quarter, which raises concerns about insider confidence. However, the potential upside is supported by analyst targets suggesting a price increase to $24 to $37 in the near future, depending on the successful progression of clinical trials for ALTO-207.